Q2 2016
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
XLRN | New | Acceleron Pharma Inc | $50,292,000 | – | 1,480,060 | – | 83.36% | – |
ALIM | New | Alimera Sciences Inc | $3,873,000 | – | 3,148,355 | – | 6.42% | – |
PULM | New | Pulmatrix Inc | $3,120,000 | – | 1,591,862 | – | 5.17% | – |
CERU | New | Cerulean Pharma Inc | $3,047,000 | – | 1,437,441 | – | 5.05% | – |
Q4 2015
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
CERU | Exit | Cerulean Pharma Inc | $0 | – | -1,437,441 | – | -9.25% | – |
ALIM | Exit | Alimera Sciences Inc | $0 | – | -3,148,355 | – | -12.23% | – |
PULM | Exit | Pulmatrix Inc | $0 | – | -1,591,862 | – | -13.74% | – |
XLRN | Exit | Acceleron Pharma Inc | $0 | – | -1,480,060 | – | -64.78% | – |
Q3 2015
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
XLRN | Sell | Acceleron Pharma Inc | $36,853,000 | -38.3% | 1,480,060 | -21.6% | 64.78% | +4.3% |
Q2 2015
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
XLRN | New | Acceleron Pharma Inc | $59,715,000 | – | 1,887,319 | – | 62.12% | – |
PULM | New | Pulmatrix Inc | $15,282,000 | – | 1,591,862 | – | 15.90% | – |
ALIM | New | Alimera Sciences Inc | $14,514,000 | – | 3,148,355 | – | 15.10% | – |
CERU | New | Cerulean Pharma Inc | $6,612,000 | – | 1,437,441 | – | 6.88% | – |
Q4 2014
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
CERU | Exit | Cerulean Pharma Inc | $0 | – | -1,437,441 | – | -5.62% | – |
ALIM | Exit | Alimera Sciences Inc | $0 | – | -3,148,355 | – | -15.81% | – |
XLRN | Exit | Acceleron Pharma Inc | $0 | – | -2,803,645 | – | -78.57% | – |
Q2 2014
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
XLRN | New | Acceleron Pharma Inc | $95,240,000 | – | 2,803,645 | – | 77.81% | – |
ALIM | New | Alimera Sciences Inc | $18,827,000 | – | 3,148,355 | – | 15.38% | – |
CERU | New | Cerulean Pharma Inc | $8,337,000 | – | 1,437,441 | – | 6.81% | – |